FindTrial
Sign In

Optimization of Dosing Regimens and Mechanistic Exploration of Novel Tetracyclines in Patients with Drug-Resistant Bacterial Infections

Optimization of Dosing Regimens and Mechanistic Exploration of Novel Tetracyclines in Patients with Drug-Resistant Bacterial Infections

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126465
Enrollment
Unknown
Registered
2026-06-09
Start date
2026-06-09
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory tract infection, Skin and soft tissue infection (SSTI), Bloodstream infection (BSI), Intra-abdominal infection (IAI), Urinary tract infection (UTI)

Interventions

Eravacycline arm:None
Omadacycline arm:None

Sponsors

The First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Adult patients with infections who received eravacycline or omadacycline for more than 72 consecutive hours.

Exclusion criteria

Exclusion criteria: 1.Blood samples collected from patients after irregular dosing and repeated drug discontinuation during the course of treatment. 2.Patients who received treatment for less than 7 days were excluded from the efficacy evaluation.

Design outcomes

Primary

MeasureTime frame
Infection improvement after 7 days of treatment;—

Countries

China

Contacts

Public ContactChen SiYing

The First Affiliated Hospital of Xi'an Jiaotong University

ychen0326@163.com+86 29 8532 3537

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026